These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35451909)

  • 1. Real-world practice patterns and characteristics of adverse events with selexipag in Korean patients with pulmonary arterial hypertension.
    Chang SA; Lee SH; Choi JH; Chung WJ; Choi JY; Kim HK; Jung HO; Park SM; Kim WJ; Jung SY; Chang HJ
    Expert Opin Drug Saf; 2022 Nov; 21(11):1423-1432. PubMed ID: 35451909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE.
    Kim NH; Hemnes AR; Chakinala MM; Highland KB; Chin KM; McLaughlin V; Zhao C; Narayan V; Farber HW
    J Heart Lung Transplant; 2021 Apr; 40(4):279-288. PubMed ID: 33526303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study.
    Klose H; Chin KM; Ewert R; Gall H; Parambil J; Poch D; Seyfarth HJ; Axelsen LN; Hsu Schmitz SF; Stein C; Preston IR
    Respir Res; 2021 Feb; 22(1):34. PubMed ID: 33536021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
    Galiè N; Gaine S; Channick R; Coghlan JG; Hoeper MM; Lang IM; McLaughlin VV; Lassen C; Rubin LJ; Hsu Schmitz SF; Sitbon O; Tapson VF; Chin KM
    Adv Ther; 2022 Jan; 39(1):796-810. PubMed ID: 34727317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
    Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
    J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
    Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
    Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selexipag for the treatment of pulmonary arterial hypertension.
    Noel ZR; Kido K; Macaulay TE
    Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
    Bruderer S; Hurst N; Remenova T; Dingemanse J
    Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experience with Selexipag to Treat Pulmonary Arterial Hypertension].
    Karelkina EV; Goncharova NS; Simakova MA; Moiseeva OM
    Kardiologiia; 2020 Mar; 60(4):36-42. PubMed ID: 32394855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selexipag for the Treatment of Pulmonary Arterial Hypertension.
    Sitbon O; Channick R; Chin KM; Frey A; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; Preiss R; Rubin LJ; Di Scala L; Tapson V; Adzerikho I; Liu J; Moiseeva O; Zeng X; Simonneau G; McLaughlin VV;
    N Engl J Med; 2015 Dec; 373(26):2522-33. PubMed ID: 26699168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Honorato Pérez J
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.
    Takatsuki S; Nakayama T; Shimizu Y; Kawai R; Matsuura H
    Cardiol Young; 2023 Feb; 33(2):196-200. PubMed ID: 35383553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selexipag for the treatment of children with pulmonary arterial hypertension: First multicenter experience in drug safety and efficacy.
    Hansmann G; Meinel K; Bukova M; Chouvarine P; Wåhlander H; Koestenberger M;
    J Heart Lung Transplant; 2020 Jul; 39(7):695-706. PubMed ID: 32362477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series.
    Fanous SM; Janmohamed M
    Am J Health Syst Pharm; 2018 Dec; 75(23):1877-1881. PubMed ID: 30301721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
    Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
    Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world experience of selexipag titration in pulmonary arterial hypertension.
    Cullivan S; Natarajan A; Boyle N; McCormack C; Gaine S; McCullagh B
    Br J Cardiol; 2021; 28(3):32. PubMed ID: 35747707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case Report of a Patient With Pulmonary Arterial Hypertension Transitioned From Inhaled Iloprost to Selexipag.
    Verlinden NJ; Walter C; Raina A; Benza RL
    J Pharm Pract; 2021 Dec; 34(6):980-983. PubMed ID: 32912036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
    Baker WL; Darsaklis K; Singhvi A; Salerno EL
    Ann Pharmacother; 2017 Jun; 51(6):488-495. PubMed ID: 28478717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.